ID   TE 671 Subline No.2
AC   CVCL_2731
SY   TE671 Subline No.2; TE671 Subline 2; TE671 Line, subline 2
DR   CLO; CLO_0009318
DR   CLDB; cl4499
DR   CLDB; cl4500
DR   BCRC; 60324
DR   BioSample; SAMN03151902
DR   cancercelllines; CVCL_2731
DR   CCRID; 1101HUM-PUMC000266
DR   ECACC; 94052610
DR   ICLC; HTL97021
DR   KCLB; 28805
DR   Wikidata; Q54971991
RX   Patent=US4789640;
RX   PubMed=2911385;
RX   PubMed=2993532;
RX   PubMed=2739733;
RX   PubMed=20143388;
WW   https://www.atcc.org/en/support/technical-support/faqs/te671-sub-line-2-atcc-crl-8805
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Group: Patented cell line.
CC   Problematic cell line: Contaminated. Parent cell line (TE 671) has been shown to be a RD derivative (PubMed=2739733; PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00347.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8805.
CC   Population: Caucasian.
CC   Doubling time: 27 hours (PubMed=2993532).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Discontinued: BCRC; 60324; true.
CC   Discontinued: ECACC; 94052610; probable.
CC   Derived from site: In situ; Pelvis, muscle; UBERON=UBERON_0001325.
ST   Source(s): ATCC; CCRID
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 13
ST   D16S539: 10,11
ST   D18S51: 13
ST   D19S433: 11,14
ST   D21S11: 28,29
ST   D2S1338: 23
ST   D3S1358: 15,17
ST   D5S818: 10,11
ST   D7S820: 8,12
ST   D8S1179: 11,15
ST   FGA: 20,21
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 18
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1756 ! TE 671
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   Patent=US4789640;
RA   Lindstrom J.M.;
RT   "Assays for myasthenia gravis.";
RL   Patent number US4789640, 06-Dec-1988.
//
RX   PubMed=2911385; DOI=10.1038/337311c0;
RA   Stratton M.R., Reeves B.R., Cooper C.S.;
RT   "Misidentified cell.";
RL   Nature 337:311-312(1989).
//
RX   PubMed=2993532; DOI=10.1097/00005072-198509000-00003;
RA   Jacobsen P.F., Jenkyn D.J., Papadimitriou J.M.;
RT   "Establishment of a human medulloblastoma cell line and its
RT   heterotransplantation into nude mice.";
RL   J. Neuropathol. Exp. Neurol. 44:472-485(1985).
//
RX   PubMed=2739733; DOI=10.1038/340106b0;
RA   Chen T.-R., Dorotinsky C.S., Macy M.L., Hay R.J.;
RT   "Cell identity resolved.";
RL   Nature 340:106-106(1989).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//